Stockreport

Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting [Yahoo! Finance]

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that new data evaluating XOSPATA™ (gilteritinib) across FM [Read more]